Encouraging Potential Treatment Data for Fibromyalgia, PTSD Presented by Tonix Pharmaceuticals

Encouraging Potential Treatment Data for Fibromyalgia, PTSD Presented by Tonix Pharmaceuticals
Tonix Pharmaceuticals has presented data for TNX-102 SL (cyclobenzaprine [CBP] HCI sublingual tablets, 2.8 mg), its investigational new drug, at the American Society for Clinical Pharmacology and Therapeutics 2016 Annual Meeting, held March 8 -12 in San Diego, California. The poster presentation, “Rapid Sublingual Absorption on Cyclobenzaprine (CBP) with Basifying Agents: Prospect for Bedtime Treatment of Fibromyalgia Syndrome (FM),” showed the drug’s potential for the treatment of post-traumatic stress disorder (PTSD) and for the long-term management of fibromyalgia. TNX-102 SL has been approved by the U.S. FDA as an Investigational New Drug, but it has not yet been approved as a therapy for any condition. Also, the FDA has conditionally accepted the proposed trade name Tonmya for TNX-102 SL. New York City-based Tonix is now evaluating TNX-102 SL in the randomized, double-blind, placebo-controlled, registration-quality Phase II AtEase clinical trial in PTSD triggered by military functions; and in the randomized, double-blind, placebo-controlled 12-
Subscribe or to access all post and page content.